Open access · CC-BY
via OpenAlex
Fasting and rapamycin: diabetes versus benevolent glucose intolerance
Cell Death and Disease · 2019 · ▲ 75 citations
Deregulated nutrient-sensing
Intermittent fasting
Rapamycin / mTOR inhibition
Metformin
Exercise
Human
Abstract
mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">Rapamycin(definition) (Sirolimus) slows aging, extends life span, and prevents age-related diseases, including diabetic complications such as retinopathy. Puzzlingly, rapamycin can induce insulin sensitivity, but may also induce insulin resistance or glucose intolerance without insulin resistance. This mirrors the effect of fasting and very low calorie diets, which improve insulin sensitivity and reverse type 2 diabetes, but also can cause a form of glucose intolerance known as benevolent pseudo-diabetes. There is no indication that starvation (benevolent) pseudo-diabetes is detrimental. By contrast, it is associated with better health and life extension. In transplant patients, a weak association between rapamycin/everolimus use and hyperglycemia is mostly due to a drug interaction with calcineurin inhibitors. When it occurs in cancer patients, the hyperglycemia is mild and reversible. No hyperglycemic effects of rapamycin/everolimus have been detected in healthy people. For antiaging purposes, rapamycin/everolimus can be administrated intermittently (e.g., once a week) in combination with intermittent carbohydrate restriction, physical exercise, and metformin.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1038/s41419-019-1822-8
- Canonical
- link ↗
- Fetched
- 2026-07-08 MST
Cite this
APA
Blagosklonny, M.V. (2019). Fasting and rapamycin: diabetes versus benevolent glucose intolerance. <em>Cell Death and Disease</em>. https://doi.org/10.1038/s41419-019-1822-8
Vancouver
Blagosklonny MV. Fasting and rapamycin: diabetes versus benevolent glucose intolerance. Cell Death and Disease. 2019. doi:10.1038/s41419-019-1822-8.
BibTeX
@article{mikhail2019Fastin,
title = {Fasting and rapamycin: diabetes versus benevolent glucose intolerance},
author = {Mikhail V. Blagosklonny},
journal = {Cell Death and Disease},
year = {2019},
doi = {10.1038/s41419-019-1822-8},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cell Cycle 2011
Open access · OA
Rapamycin-induced glucose intolerance: Hunger or starvation diabetes
Journal of Translational Medicine 2023
Open access · CC-BY
Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing
Poznan University of Medical Sciences 2020
Open access · US-GOV
Assessment of Physical Effort in People With Newly Diagnosed Type 1 Diabetes Mellitus and Its Impact on: Partial Clinical Remission, Insulin Resistance, HDL Cholesterol Function, Immune Function and Length of Life.
Frontiers in Physiology 2019
Open access · CC-BY
Mitochondrial (Dys)function and Insulin Resistance: From Pathophysiological Molecular Mechanisms to the Impact of Diet
Frontiers in Aging Neuroscience 2017
Open access · CC-BY
Insulin Resistance and Alzheimer’s Disease: Bioenergetic Linkages
The Journal of Clinical Endocrinology & Metabolism 2002
Citation only